Latest Off-label use Stories
The resources doctors use to get important information about indications and reimbursement for use of cancer drugs off-label may be out-of-date and incomplete, according to a study led by researchers in the Duke Comprehensive Cancer Center.
- PDUFA Date for Cinryze for Acute HAE Indication is June 3, 2009 - EXTON, Pa., Feb. 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the U.S.
Medicare has extended its coverage for cancer drugs to incorporate several treatments that do not have the Food and Drug Administration's approval.
$515 Million Criminal Fine is Largest Individual Corporate Criminal Fine in History; Civil Settlement Up To $800 Million WASHINGTON, Jan.
WASHINGTON, Dec. 30 /PRNewswire-USNewswire/ -- The Coalition for 21st Century Medicine strongly opposes the citizen petition filed by Genentech, Inc. on December 5, 2008, seeking to restrict the ability of laboratories to offer diagnostic tests to physicians and patients.
EXTON, Pa., Dec. 1 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S.
Doctors and patients should be concerned about antipsychotic and antidepressant drugs being prescribed for unapproved conditions, U.S.
Two physicians describe how some drug companies may promote off-label use -- prescribing drugs for a purpose outside of their approved use.
By Rita Rubin Baylor College of Medicine neurologist Joseph Jankovic is a patient man. With the Food and Drug Administration's OK, Jankovic has studied the drug tetrabenazine since 1979.
WASHINGTON, Sept. 29 /PRNewswire/ -- The government's investigation into Cephalon Inc.'s illegal marketing practices that culminated in today's $425,000,000 settlement and guilty plea by the pharmaceutical company began in January 2003 with a Cephalon sales representative in Ohio.
- a meat pie that is usually eaten at Christmas in Quebec